Home - Clinical Trials Arena
WEBAligos reports positive data from Phase IIa MASH treatment trial. In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat. News.
Analysis - Clinical Trials Arena
WEBAlzheimer’s heterogeneity necessitates diverse enrollment in clinical trials. Clinical trials are the final bridge to cross before a new treatment can reach patients. Though Alzheimer's disease affects individuals….
Outsourcing trends in clinical trials: How one company is …
WEBSep 18, 2023 · George Sawicki (GS): There is certainly a gravitational pull to the FSP model. Many larger FSP players have now been acquired by CROs, which has made them even bigger. We’ve noticed a lot more traction for a company that’s our size; companies that use more of a boutique shop while always ensuring the number one priority is quality.
Biosimilars: top 10 pharma companies leading the way
WEBJan 20, 2022 · Yesterday (19 January), using the same Thematic Research ecosystem, Clinical Trials Arena revealed the top pharma companies best equipped with artificial intelligence. According to our analysis, Novartis, Pfizer, Catalent, Amgen, Biogen, Patheon, Shanghai Henlius Biotech, Viatris, Celltrion, and Samsung Bioepis are …
Linzess (linaclotide) for the Treatment of Irritable Bowel Syndrome ...
WEBJun 2, 2023 · AbbVie and Ironwood develop and commercialise linaclotide in all other global territories. Linzess is available as white to off-white opaque hard gelatine capsules in three dosage strengths, 72mcg, 145mcg and 290mcg, for oral administration.
Ionis’ donidalorsen sodium for HAE sees an 8-point spike in FDA
WEBApr 15, 2021 · As of 31 March, the likelihood of approval (LoA) for Ionis Pharmaceuticals’ IONIS-PKK-LRx (donidalorsen sodium) for hereditary angioedema (HAE) rose 8 points in the aftermath of positive topline Phase II results, according to GlobalData’s LoA data. The 20-patient Phase II met its primary endpoint of reduction in monthly HAE attacks, with a 90% mean reduction in weeks 1-17 (p<0.001) and a ...
Zolgensma for the Treatment of Spinal Muscular Atrophy
WEBZolgensma® is an AAV9-based gene therapy designed to deliver a copy of SMN1 gene encoding human SMN protein. Credit: Novartis Pharmaceuticals. SMA is caused due to the insufficient expression of survival motor neuron (SMN) protein. Credit: Emw. Zolgensma® (onasemnogene abeparvovec-xioi) is the first gene therapy indicated to treat spinal ...
Saxenda (liraglutide) for the Treatment of Obesity, US
WEBAug 4, 2023 · Saxenda (liraglutide (rDNA origin)) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for the treatment of obesity and chronic weight management.. Discovered and developed by Denmark-based pharmaceutical company Novo Nordisk, Saxenda is available as a solution in pre-filled, multi-dose pens that delivers ...
Tesofensine Anti-Obesity Medication - Clinical Trials Arena
WEBDec 14, 2008 · Dose-dependent adverse gastrointestinal effects were observed with tesofensine in the clinical trials in addition to increases in blood pressure and heart. However, at the anticipated therapeutic dose of 0.5mg, discontinuations for adverse effects with tesofensine were similar to placebo (8%). In …
Clinical Trial Survey Questions & Responses - Clinical Trials Arena
WEBThe polls and surveys dashboard gives valuable insights on topics of interest to industry business professionals and shows how perceptions on these topics have changed over time. Hard data and deep insights on clinical trials strategy & operations. Comprehensive dashboard showing the collective responses to survey questions presented to ...